10-Year Follow-Up Shows Sustained Drug-Free Remission After Early pSpA Treatment

The CRESPA trial's 10-year follow-up evaluated 49 of the original 60 patients with early peripheral spondyloarthritis who had been randomized to golimumab or placebo. The study reported that 81.6% were in clinical remission and 30.6% achieved longstanding drug-free remission, with patients lacking baseline psoriasis significantly more likely to reach drug-free remission (48.1% of non-psoriatic patients, OR 9.1). The authors state these findings suggest early, intensive treatment may enable long-term disease control and drug-free remission in a subset of patients.

Most relevant for: Patients with early peripheral spondyloarthritis, including those with and without concurrent psoriasis.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.